Home › NDC Lookup › RxCUI directory › RxCUI 2625909

1.5 ML lenacapavir 309 MG/ML Injection [Sunlenca] — RxCUI 2625909

Name: 1.5 ML lenacapavir 309 MG/ML Injection [Sunlenca] (RxCUI 2625909)
Creator: Brian Staiger, PharmD

RxNorm drug concept · Semantic branded drug

RxCUI 2625909 Semantic branded drug · SBD ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by Dr. Brian Staiger, PharmD

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2625909

Official name1.5 ML lenacapavir 309 MG/ML Injection [Sunlenca]

Concept typeSemantic branded drug (SBD)

RxNorm statusCurrent RxNorm concept

Also known as1.5 ML Sunlenca 309 MG/ML Injection; Sunlenca 463.5 MG in 1.5 ML Injection; Sunlenca 463.5 MG per 1.5 ML Injection

FDA products mapped3

Package NDCs mapped5

Reported Medicaid activity (SDUD)746 prescriptions · 6 state & territory Medicaid programs · latest period Q4 2025

RxNorm release07/06/2026

Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Lenacapavir Oral: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist

Lenacapavir works by targeting the HIV virus's outer protein shell — called the capsid — which disrupts its ability to replicate. The oral tablets serve a specific purpose at the s...
What exactly does lenacapavir do, and why do I need the tablets if there's also an injection?
Yes, absolutely — this is one of the most important things to know. You must be tested for HIV-1 before every single injection using a sensitive FDA-approved test, not just when yo...
I'm taking Yeztugo to prevent HIV — do I still need to get tested regularly?

📖 Read our full Lenacapavir Oral guide →

🕸️ Concept Web — How 1.5 ML lenacapavir 309 MG/ML Injection [Sunlenca... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.

This page's concept 1.5 ML lenacapavir 309 MG/ML Injection [Sunlenca] RxCUI 2625909 Semantic branded drug · SBD

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

Ingredients 1

The active substance itself — no strength, form, or brand attached yet.
- Lenacapavir 2625651 IN
Brand names 1

The same medicine's trade names. A brand name alone says nothing about strength or form.
- Sunlenca 2625891 BN
Dose forms 6

The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
- Lenacapavir Injection 2625903 SCDF
- Lenacapavir Injectable Product 2625902 SCDG
- Lenacapavir Injection [Sunlenca] 2625908 SBDF
- Sunlenca Injectable Product 2625907 SBDG
- Injection 1649574 DF
- Injectable Product 1151126 DFG
Clinical & branded drugs 3

Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
- 1.5 ML lenacapavir 309 MG/ML Injection 2625904 SCD
- Lenacapavir 309 MG/ML 2625901 SCDC
- Lenacapavir 309 MG/ML [Sunlenca] 2625906 SBDC
Packs 2

Fixed collections of drugs packaged and sold together, like dose packs.
- {2 (1.5 ML lenacapavir 309 MG/ML Injection [Sunlenca]) } Pack [Sunlenca 927 MG Kit] 2625912 BPCK
- {2 (1.5 ML lenacapavir 309 MG/ML Injection) } Pack 2625911 GPCK

Showing up to 8 concepts per family — 13 of 13 stored related concepts drawn.

These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

1.5 ML lenacapavir 309 MG/ML Injection SCD · 2625904
{2 (1.5 ML lenacapavir 309 MG/ML Injection) } Pack GPCK · 2625911
Lenacapavir 309 MG/ML SCDC · 2625901
Lenacapavir Injection SCDF · 2625903
Lenacapavir Injectable Product SCDG · 2625902

Brand-Name Concepts

{2 (1.5 ML lenacapavir 309 MG/ML Injection [Sunlenca]) } Pack [Sunlenca 927 MG Kit] BPCK · 2625912
Lenacapavir 309 MG/ML [Sunlenca] SBDC · 2625906
Lenacapavir Injection [Sunlenca] SBDF · 2625908
Sunlenca Injectable Product SBDG · 2625907
Sunlenca BN · 2625891

📦 FDA Products & Package NDCs

3 products · 5 package NDCs

5 package NDCs map to RxCUI 2625909 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.

Package NDC	Package	Brand / generic name	Labeler	Marketing start
61958-3001-01	1 POUCH in 1 CARTON (61958-3001-1) / 1 BLISTER PACK in 1 PO...	Sunlenca	Gilead Sciences, Inc.	2022-12-22
61958-3001-02	1 POUCH in 1 CARTON (61958-3001-2) / 1 BLISTER PACK in 1 PO...	Sunlenca	Gilead Sciences, Inc.	2022-12-22
61958-3001-03	4 TABLET, FILM COATED in 1 BOTTLE, PLASTIC (61958-3001-3)	Sunlenca	Gilead Sciences, Inc.	2024-11-13
61958-3002-01	1 KIT in 1 CARTON (61958-3002-1) * 1.5 mL in 1 VIAL (61958...	Sunlenca	Gilead Sciences, Inc.	2022-12-22
61958-3005-01	1 KIT in 1 CARTON (61958-3005-1) * 1.5 mL in 1 VIAL (61958...	Sunlenca	Gilead Sciences, Inc.	2025-03-18

Observed labelers: Gilead Sciences, Inc. (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.

Code	Descriptor	Mapped packages	Sources
J1961	Inj lenacapavir (hiv tx) 1mg	2	CMS

⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7

openFDA export observedJul 14, 2026

RxNorm release07/06/2026

Methodology2026-07-full-catalog-v1

A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.

This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.